Europe (WHO region) vs Papua New Guinea: Previously treated cases tested for RR-/MDR-TB
Europe (WHO region)
90.0%
in 2024
Papua New Guinea
100.0%
in 2024
Europe (WHO region) rank
2nd
Papua New Guinea rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Europe (WHO region)
- Papua New Guinea
How they compare
Papua New Guinea currently reports 100.0% against 90.0% in Europe (WHO region), a difference of 10.0%.
That makes Papua New Guinea's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 2 times across 5 shared years of data; in 2015 it was Papua New Guinea ahead.
Europe (WHO region) ranks 2nd and Papua New Guinea ranks 1st of 11 groups.
Across the 2 decades both report, Europe (WHO region) averaged higher in 1 and Papua New Guinea in 1.
Head to head by decade
| Decade | Europe (WHO region) | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 59.3% | 43.3% | 16.0% | Europe (WHO region) |
| 2020s | 93.0% | 100.0% | 7.0% | Papua New Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Europe (WHO region) or Papua New Guinea?
- Papua New Guinea, at 100.0% against 90.0% in Europe (WHO region) as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Europe (WHO region) and Papua New Guinea?
- 10.0%, with Papua New Guinea ahead.
- How many years of comparable data are there for Europe (WHO region) and Papua New Guinea?
- 5 years are reported by both, from 2015 to 2024.
- How do Europe (WHO region) and Papua New Guinea rank globally for previously treated cases tested for rr-/mdr-tb?
- Europe (WHO region) ranks 2nd and Papua New Guinea ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.